For the quarter ending 2025-06-30, SCPH had -$34,846K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-06-30 |
|---|---|
| Stock-based compensation | 2,814 |
| Net loss | -37,766 |
| Amortization expense - right-of-use leased assets - operating | 119 |
| Prepaid expenses and other assets | -670 |
| Inventory | 805 |
| Accounts receivable | 7,688 |
| Accounts payable, accrued expenses and other liabilities | 5,101 |
| Depreciation expense | 8 |
| Fair value adjustment to term loan | -150 |
| Fair value adjustment to revenue purchase and sale liability | 4,312 |
| Allowance for excess, damaged and obsolete inventory | 135 |
| Net cash used in operating activities | -33,250 |
| Proceeds from employee stock purchase plan | 316 |
| Payment on revenue purchase and sale liability | 1,912 |
| Net cash provided by (used in) financing activities | -1,596 |
| Net decrease in cash and cash equivalents | -34,846 |
scPharmaceuticals Inc. (SCPH)
scPharmaceuticals Inc. (SCPH)